Yasuyuki Kojima

5PUBLICATIONS
17CO-AUTHORS
Environmental epidemiologyCancer therapy (excl. chemotherapy and radiation therapy)Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Jul 08, 2026
Efficacy and safety of eribulin mesylate vs. docetaxel or paclitaxel, combined with trastuzumab and pertuzumab, as first-line treatment for HER2-positive locally advanced or metastatic breast cancer: updated subgroup analyses of JBCRG-M06/EMERALD.

|Jun 10, 2026
Quality-of-life assessment in the randomized JBCRG-M06/EMERALD study of eribulin plus dual HER2 blockade in HER2-positive locally advanced or metastatic breast cancer.

|Feb 25, 2025
Causative Genes of Homologous Recombination Deficiency (HRD)-Related Breast Cancer and Specific Strategies at Present.

Seigo Nakamura, Yasuyuki Kojima, Sayoko Takeuchi

|Apr 03, 2021
Meta-analysis of nanoparticle albumin-bound paclitaxel used as neoadjuvant chemotherapy for operable breast cancer based on individual patient data (JBCRG-S01 study).

Manabu Futamura, Mari Oba, Norikazu Masuda

|Feb 25, 2021
Antiemetic Efficacy of Adding Olanzapine 5 mg to Aprepitant, Palonosetron and Dexamethasone-Sparing After Day Two for Cancer Patients Receiving Anthracycline and Cyclophosphamide.

Marii Suehiro, Yasuyuki Kojima, Masaki Takahashi

Pageof 1

Frequent Collaborators

3 joint publications

Norikazu Masuda

2 joint publications

Toshinari Yamashita

2 joint publications

Tsuguo Iwatani

2 joint publications

Shigehira Saji